journal
MENU ▼
Read by QxMD icon Read
search

Veterinary and Comparative Oncology

journal
https://www.readbyqxmd.com/read/28799187/safety-evaluation-of-combination-carboplatin-and-toceranib-phosphate-palladia-in-tumour-bearing-dogs-a-phase-i-dose-finding-study
#1
R M Wouda, S E Hocker, M L Higginbotham
Combining conventional cytotoxic maximum tolerated dose (MTD) chemotherapy with low-dose metronomic and/or anti-angiogenic agents is a exciting area of oncologic research. The objective of this study was to establish the MTD, safety and adverse event (AE) profile of 1 such drug combination. This prospective phase I dose-finding clinical trial assumed an open-label 3 + 3 cohort design. Client-owned dogs with 1 or more cytologically and/or histologically confirmed and macroscopically measurable, naive or recurrent, malignant tumours, were enrolled...
August 10, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28766920/temozolomide-alone-or-in-combination-with-doxorubicin-as-a-rescue-agent-in-37-cases-of-canine-multicentric-lymphoma
#2
E Treggiari, J W Elliott, S J Baines, L Blackwood
Temozolomide (TMZ) is an alkylating agent previously used in conjunction with doxorubicin (DOX) to treat dogs with relapsed lymphoma. However, there are very limited data for this drug when used as single agent. The aim of this retrospective study was to evaluate the efficacy and toxicity of TMZ in dogs with relapsed multicentric lymphoma that failed multi-agent chemotherapy protocols, and compare the outcome to a group of dogs receiving the same drug in combination with DOX. Twenty-six patients were included in the TMZ group and 11 in the TMZ/DOX group...
August 2, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28752538/clinicopathologic-features-of-lingual-canine-t-zone-lymphoma
#3
L J Harris, E D Rout, K L Hughes, J D Labadie, B Boostrom, J A Yoshimoto, C M Cannon, P R Avery, E J Ehrhart, A C Avery
Canine T-zone lymphoma (TZL) is a subtype of T-cell lymphoma characterized by unique histologic pattern and cytomorphology, immunophenotypic loss of CD45 expression, and an indolent clinical behaviour. Dogs with TZL typically present with 1 or more enlarged lymph nodes and/or lymphocytosis. We describe a novel extranodal presentation of TZL involving the tongue. Twelve dogs with tongue masses were diagnosed with lingual TZL based on a variable combination of immunophenotyping via flow cytometry, cytology, histopathology, immunohistochemistry and/or PCR for antigen receptor rearrangement (PARR) assay...
July 27, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28741887/linac-based-stereotactic-radiation-therapy-for-canine-non-lymphomatous-nasal-tumours-29-cases-2013-2016
#4
T L Gieger, M W Nolan
Twenty-nine dogs were treated with linac-based stereotactic radiation therapy (SRT) for non-lymphomatous nasal tumours. Only dogs with a follow-up time >365 days were included in this retrospective analysis. No dogs had evidence of distant metastasis at diagnosis. Treatment was planned and a total of 30 Gy in 3 daily 10 Gy fractions was delivered using intensity-modulation, cone-beam CT-based image guidance and a robotic treatment couch. Clinical signs improved in all cases. Nineteen dogs had CT scans 3-4 months post-SRT and all had partial or complete tumour response...
July 25, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28660709/patient-characteristics-prognostic-factors-and-outcome-of-dogs-with-high-grade-primary-mediastinal-lymphoma
#5
E L Moore, W Vernau, R B Rebhun, K A Skorupski, J H Burton
The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme...
June 28, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28643878/frameless-stereotactic-radiotherapy-alone-and-combined-with-temozolomide-for-presumed-canine-gliomas
#6
M Dolera, L Malfassi, C Bianchi, N Carrara, S Finesso, S Marcarini, G Mazza, S Pavesi, M Sala, G Urso
We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation. Overall and disease-specific survival times were estimated. Thirty dogs were palliated, 22 dogs were treated with RT and 20 with RT + TMZ. Complete and partial responses were observed in 63.2% and 90.9% of patients in the RT and RT + TMZ arms, respectively, that were alive at 1 year. Median survival in the palliation arm was 94 days (95% conformity index [CI] 87÷101)...
June 23, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28620942/a-dose-escalation-study-of-combretastatin-a4-phosphate-in-healthy-dogs
#7
E Abma, P Smets, S Daminet, I Cornelis, K De Clercq, Y Ni, L Vlerick, H de Rooster
Combretastatin A4-Phosphate (CA4P) is a vascular disrupting agent revealing promising results in cancer treatments for humans. The aim of this study was to investigate the safety and adverse events of CA4P in healthy dogs as a prerequisite to application of CA4P in dogs with cancer. Ten healthy dogs were included. The effects of escalating doses of CA4P on physical, haematological and biochemical parameters, systolic arterial blood pressure, electrocardiogram, echocardiographic variables and general wellbeing were characterised...
June 16, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28621057/prospective-evaluation-of-toceranib-phosphate-in-metastatic-canine-osteosarcoma
#8
T Laver, C A London, D M Vail, B J Biller, J Coy, D H Thamm
Efficacious therapies for measurable metastatic canine osteosarcoma (OSA) are generally lacking. Preliminary retrospective studies suggested that approximately 50% of dogs with measurable metastatic OSA experienced clinical benefit (objective response or clinically meaningful disease stabilisation) following toceranib (TOC) treatment. The purpose of this clinical trial was to prospectively evaluate the clinical outcome following TOC treatment in dogs with measurable pulmonary metastatic OSA. A secondary goal was to identify potential biomarkers of clinical benefit by measuring changes in plasma vascular endothelial growth factor (VEGF) and circulating regulatory T-cell (Treg) percentage...
June 15, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28621004/epirubicin-in-the-treatment-of-canine-histiocytic-sarcoma-sequential-alternating-and-rescue-chemotherapy
#9
S L Mason, R Finotello, L Blackwood
The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine. Medical records of dogs with a diagnosis of HS that were treated with both lomustine and epirubicin were retrospectively evaluated. Of 29 dogs receiving epirubicin alternating with, or subsequent to lomustine treatment, including in a rescue setting, response to epirubicin could be assessed in 20 with an overall response rate (ORR) of 29% and biological response rate (BRR) of 71%...
June 15, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28608404/apoptotic-intrinsic-pathway-proteins-predict-survival-in-canine-cutaneous-mast-cell-tumours
#10
C N Barra, B M Macedo, K G Cadrobbi, L H Pulz, G C Huete, S R Kleeb, J G Xavier, J L Catão-Dias, A T Nishiya, H Fukumasu, R F Strefezzi
Mast cell tumours (MCTs) are the most frequent canine round cell neoplasms and show variable biological behaviours with high metastatic and recurrence rates. The disease is treated surgically and wide margins are recommended. Adjuvant chemotherapy and radiotherapy used in this disease cause DNA damage in neoplastic cells, which is aimed to induce apoptotic cell death. Resisting cell death is a hallmark of cancer, which contributes to the development and progression of tumours. The aim of this study was to investigate the expression of the proteins involved in the apoptotic intrinsic pathway and to evaluate their potential use as prognostic markers for canine cutaneous MCTs...
June 13, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28589573/in-vitro-and-in-vivo-effect-of-flutamide-on-steroid-hormone-secretion-in-canine-and-human-inflammatory-breast-cancer-cell-lines
#11
S Caceres, B Monsalve, L Peña, P J de Andres, A Alonso-Diez, M J Illera, W A Woodward, J M Reuben, G Silvan, J C Illera
The aim was to study the effects of flutamide on cell proliferation, in vivo tumour growth and steroid production in canine and human IBC cell lines. IPC-366 and SUM149 cell cultures were exposed to flutamide concentrations for 72 hours. Additionally, IPC-366 and SUM149 xenotransplanted mice were treated subcutaneously with flutamide 3 times a week for 2 weeks. Steroid hormones determination in culture media, serum and tumour homogenates (pregnenolone, progesterone, androstenedione, testosterone, dihydrotestosterone, 17β-oestradiol and oestrone sulphate) were assayed by EIA...
June 6, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28560846/outcome-following-treatment-of-feline-gastrointestinal-mast-cell-tumours
#12
L E Barrett, K Skorupski, D C Brown, N Weinstein, C Clifford, A Szivek, S Haney, S Kraiza, E L Krick
Prognosis of feline gastrointestinal mast cell tumours (FGIMCT), based on limited available literature, is described as guarded to poor, which may influence treatment recommendations and patient outcome. The purpose of this study is to describe the clinical findings, treatment response, and outcome of FGIMCT. Medical records of 31 cats diagnosed with and treated for FGIMCT were retrospectively reviewed. Data collected included signalment, method of diagnosis, tumour location (including metastatic sites), treatment type, cause of death and survival time...
May 31, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28556532/feline-large-granular-lymphocyte-lymphoma-an-italian-society-of-veterinary-oncology-sioncov-retrospective-study
#13
R Finotello, M E Vasconi, S Sabattini, C Agnoli, C Giacoboni, M Annoni, A Dentini, G Bettini, P Guazzi, D Stefanello, E Bottero, P Mesto, R Marinelli, C De Feo, L Marconato
Feline large granular lymphocyte (LGL) lymphoma is an uncommon subtype of lymphoma characterized by a grave prognosis and scarce response to chemotherapy. There are limited reports on clinico-pathological and prognostic factors. One-hundred and 9 cats with newly diagnosed LGL lymphoma that underwent initial staging (including hematology, serum biochemistry, thoracic radiographs and abdominal ultrasound), and followed-up were retrospectively evaluated. LGL lymphoma was localized within the gastrointestinal tract with or without extra-intestinal involvement in 91...
May 29, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27549077/gastric-carcinoma-in-canines-and-humans-a-review
#14
REVIEW
S Hugen, R E Thomas, A J German, I A Burgener, P J J Mandigers
Gastric carcinoma (GC) is the most common neoplasm in the stomach of dogs. Although incidence in the general population is reported to be low, breed-specific GC has a high incidence. Median age at presentation ranges from 8 to approximately 10 years. The disease is mostly located in the lesser curvature and antropyloric region of the stomach. Unfortunately, diagnosis is usually made when the disease is at an advanced stage and, therefore, prognosis is poor. Due to similarities in clinical presentation, diagnosis, histology and prognosis, canine GC may serve as a valuable model for human GC...
September 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27412493/conformity-and-controversies-in-the-diagnosis-staging-and-follow-up-evaluation-of-canine-nodal-lymphoma-a-systematic-review-of-the-last-15-years-of-published-literature
#15
L Marconato, G A Polton, S Sabattini, M Dacasto, O A Garden, I Grant, T Hendrickx, J Henriques, G Lubas, E Morello, D Stefanello, S Comazzi
Diagnostic methods used in the initial and post-treatment evaluation of canine lymphoma are heterogeneous and can vary within countries and institutions. Accurate reporting of clinical stage and response assessment is crucial in determining the treatment efficacy and predicting prognosis. This study comprises a systematic review of all available canine multicentric lymphoma studies published over 15 years. Data concerning diagnosis, clinical stage evaluation and response assessment procedures were extracted and compared...
September 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27402031/canine-acute-leukaemia-50-cases-1989-2014
#16
A L Bennett, L E Williams, M W Ferguson, M L Hauck, S E Suter, C B Lanier, P R Hess
Acute leukaemia (AL) is a bone marrow malignancy of hematopoietic progenitors that historically is poorly responsive to treatment. With the widespread adoption of dose-intense chemotherapy, more human patients attain long-term survivals, but whether comparable progress has been made in canine AL is unknown. To investigate this question, medical records from three academic veterinary hospitals were reviewed. Fifty dogs met the criteria for AL, having excess circulating or marrow blasts, a major cytopenia(s), and no substantial lymphadenopathy...
September 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27333821/enrofloxacin-enhances-the-effects-of-chemotherapy-in-canine-osteosarcoma-cells-with-mutant-and-wild-type-p53
#17
D York, S S Withers, K D Watson, K W Seo, R B Rebhun
Adjuvant chemotherapy improves survival time in dogs receiving adequate local control for appendicular osteosarcoma, but most dogs ultimately succumb to metastatic disease. The fluoroquinolone antibiotic enrofloxacin has been shown to inhibit survival and proliferation of canine osteosarcoma cells in vitro. Others have reported that fluoroquinolones may modulate cellular responses to DNA damaging agents and that these effects may be differentially mediated by p53 activity. We therefore determined p53 status and activity in three canine osteosarcoma cell lines and examined the effects of enrofloxacin when used alone or in combination with doxorubicin or carboplatin chemotherapy...
September 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27278807/outcome-in-dogs-with-advanced-stage-3b-anal-sac-gland-carcinoma-treated-with-surgery-or-hypofractionated-radiation-therapy
#18
V Meier, G Polton, S Cancedda, M Roos, P Laganga, T Emmerson, C Rohrer Bley
Stage 3b anal sac gland carcinoma (ASGC) can be life-threatening. A surgical approach is not always possible or may be declined. Dogs with stage 3b ASGC treated with surgery or conformal radiation therapy (RT) with 8 × 3.8 Gy (total dose 30.4 Gy, over 2.5 weeks) were retrospectively evaluated. Patient characteristics, median progression-free interval (PFI) and median survival time (MST) were compared. Twenty-eight dogs were included; 15 underwent surgery, 13 underwent RT. At the time of presentation, 21% showed life-threatening obstipation and 25% showed hypercalcaemia...
September 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27278673/defect-in-nd2-cox2-atp6-and-cox3-mitochondrial-genes-as-a-risk-factor-for-canine-mammary-tumour
#19
M Surdyka, B Slaska
The aim of this study was to identify mutations in ND2, COX2, ATP6 and COX3 mitochondrial genes in canine mammary tumour, determine their association with the process of neoplastic transformation, and phenotypic traits of dogs. In total, 93 biological samples, including blood, normal and neoplastic tissue samples from 31 dogs with diagnosed malignant canine mammary tumours were analysed. DNA sequencing of genes as well as bioinformatics and statistical analyses were performed. A total of 28 polymorphic loci and 11 mutations were identified...
September 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27278268/kit-receptor-tyrosine-kinase-dysregulations-in-feline-splenic-mast-cell-tumours
#20
S Sabattini, G Barzon, M Giantin, R M Lopparelli, M Dacasto, D Prata, G Bettini
This study investigated Kit receptor dysregulations (cytoplasmic immunohistochemical expression and/or c-KIT mutations) in cats affected with splenic mast cell tumours. Twenty-two cats were included. Median survival time was 780 days (range: 1-1219). An exclusive splenic involvement was significantly (P = 0.042) associated with longer survival (807 versus 120 days). Eighteen tumours (85.7%) showed Kit cytoplasmic expression (Kit pattern 2, 3). Mutation analysis was successful in 20 cases. Fourteen missense mutations were detected in 13 out of 20 tumours (65%)...
September 2017: Veterinary and Comparative Oncology
journal
journal
40498
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"